Evidence map›Paper›PMID 40278689›Full record

ArticleToxins2025

Reply to Trosch et al. Comment on "Dashtipour et al. Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information.

Khashayar Dashtipour, Han S Lee, Aaron Ellenbogen, Rashid Kazerooni, Todd M Gross, David A Hollander, Conor J Gallagher

Abstract readLetter
In one paragraph

Article in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Khashayar DashtipourDepartment of Neurology/Movement Disorders, Loma Linda University, Loma Linda, CA 92354, USA.
Han S LeeDepartment of Neurology, The Permanente Medical Group, Greater Southern Alameda Area-San Leandro/Fremont, San Leandro, CA 94577, USA.ORCID 0009-0007-6508-2640
Aaron EllenbogenQuest Research Institute, Farmington Hills, MI 48334, USA.
Rashid KazerooniRevance Therapeutics, Nashville, TN 37203, USA.ORCID 0000-0003-3223-2597
Todd M GrossRevance Therapeutics, Nashville, TN 37203, USA.ORCID 0000-0001-5482-5313
David A HollanderRevance Therapeutics, Nashville, TN 37203, USA.
Conor J GallagherRevance Therapeutics, Nashville, TN 37203, USA.ORCID 0000-0002-5488-6594

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We thank Trosch et al [...].

Indexed as

Botulinum Toxins, Type ADeglutition DisordersMuscle WeaknessNeuromuscular AgentsTorticollisHumansBotulinum Toxins, Type ANeuromuscular Agents

Identifiers

PMID40278689
PMCPMC12031220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.